34 / 83
M
arqui
ABT
512
R
ev
A
ssoc
M
ed
B
ras
2015; 61(6):507-518
TABLE 3
(Cont.) Main results of 17 studies that evaluated the effect of drugs on pain scores.
Study
Sample
Medication
used
Number of patients
treated
Information regarding pain
(instrument used, types of
pain, etc.)
Main results and/or conclusion
Ferrero et al.
19
6 women with
colorectal
endometriosis
Letrozole
Norethis-
terone acetate
Letrozole and norethisterone acetate for
6 months
Pilot study
VAS (dysmenorrhea, non-men-
strual pelvic pain, deep dyspa-
reunia, dyschezia and gastroin-
testinal symptoms) presence and
intensity of symptoms assessed
before starting treatment and
after 3 and 6 months of treat-
ment
Prevalence and mean intensity (standard deviation) of symptoms before and
3 and 6 months after treatment.
Dysmenorrhea: 100%
7.6±1.8 NI NI
Non-menstrual pelvic pain: 83%
6±1.1 3.2±0.5 2.2±0.4
Deep dyspareunia: 83%
5.1±1.9 1.7±1.2 1.2±1.0
Dyschezia: 67%
5.1±2.0 2.0±1.5 1.2±0.9
Intensity of symptoms decreased 3 months after treatment and even further
after 6 months.
67% of patients reported being satisfied/very satisfied with respect to the
overall assessment of the effects of the treatment on symptoms.
4 patients reported side effects of treatment but due to their mild severity,
there was no interruption of treatment: bleeding (n=1), weight gain (n=1),
joint pain (n=1), and decreased libido (n=1).
The combined use of letrozole and norethisterone acetate reduces pain and
gastrointestinal symptoms.
Ferrero et al.
20
40 women
with
colorectal
endometriosis
Norethis-
terone acetate
Norethisterone acetate for 12 months
Initial sample: n=40
6 months: n=38
12 months: n=32
VAS (dysmenorrhea, CPP, deep
dyspareunia, and dyschezia),
and gastrointestinal symptoms
measured before and after 6 and
12 months of treatment
85% dysmenorrhea, 73% CPP, 67% deep dyspareunia and 68% dyschezia.
60% of patients reported being satisfied/very satisfied with respect to the overall as-
sessment of the effects of the treatment on symptoms at the end of treatment.
53% of patients reported improvement in gastrointestinal symptoms.
The administration of norethisterone acetate promoted a significant improve-
ment in the intensity of CPP, deep dyspareunia and dyschezia.
Values expressed as a mean (± standard deviation) before the beginning of
treatment and after 6 and 12 months.
Dysmenorrhea: 6.8±1.9/not available/not available
CPP: 5.5±1.3/4.1±1.8/3.5±1.6
Deep dyspareunia: 5.7±1.4/3.1±1.1/2.8±1.2
Dyschezia: 5.1±1.9/3.2±1.2/2.5±1.4
(Continue)